P-199 - EVALUATION OF QTC INTERVAL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA FOLLOWING ENFORTUMAB VEDOTIN ADMINISTRATION.

A. Yamada¹, R. Fukushi¹, T. Kadokura¹, A. Garg², M. Tang³; ¹Astellas Pharma Inc., Tokyo, Japan, ²Seagen Inc., Bothell, WA, USA, ³Astellas Pharma Inc., Northbrook, IL, USA.

Presenting Author(s)

Akihiro Yamada, PhD

Senior Manager, Clinical Pharmacology and Exploratory Development
Astellas Pharma Inc.
Chuoku, Tokyo, Japan